Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

Mitochondria, interneurons, cognition link explored

July 23, 2020

FDA approves Qutenza for neuropathic pain associated with DPN of the feet

July 22, 2020

AZP-2006 studied in phase II for progressive supranuclear palsy

July 22, 2020

Phase III CLARITY study of pimavanserin in MDD does not meet primary endpoint

July 21, 2020

SERENITY I and SERENITY II pivotal studies meet primary and secondary endpoints

July 21, 2020

RaQualia Pharma presents new SCN9A and SCN10A channel blockers

July 21, 2020

Sage Therapeutics studies SAGE-324 in phase II for essential tremor

July 20, 2020

Kringle begins phase III trial of KP-100IT for acute spinal cord injury in Japan

July 20, 2020

Samus opens phase IIa trial of PU-AD for mild Alzheimer's disease dementia

July 17, 2020

Praxis Precision Medicines patents compounds targeting human KCNT1

July 17, 2020

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 22, 2026.
‘Detargeted’ targeted gene therapy improves activity in Pompe
BioWorld
A new strategy aims to improve gene therapy for Pompe disease by optimizing both the genetic component that restores the function of a deficient lysosomal enzyme...
News in brief
BioWorld Asia
BioWorld Asia briefs for May 19, 2026
WHO declares Ebola outbreak a public health emergency of international concern
BioWorld
The threat posed by the Ebola outbreak in the Democratic Republic of Congo has intensified, with the confirmation that it is caused by the Bundibugyo species of...
Nxera Pharma prepares and tests new GPR17 antagonists
BioWorld Science
Nxera Pharma UK Ltd. has identified new uracil nucleotide/cysteinyl leukotriene receptor (GPR17; P2Y-Like) antagonists potentially useful for the treatment of...